liuchanger1984@163.com
刘莹，副研究员，硕士生导师，主要从事骨质疏松小分子药物的筛选与优化，骨质疏松症的相关基础与临床研究和破骨细胞分化机制等。近年来在Cell Death Dis、Int Immunopharmacol、Journal of Biological Chemistry等知名杂志上发表多篇SCI论文，获批国家自然科学基金青年基金资助和国防科技特区163计划12-18重点项目资助，总经费270万。授权专利2项。
主要研究领域：
1. 药物抑制破骨细胞及治疗骨质疏松的机制研究；
2. 药物对肿瘤骨转移的作用及机制研究。
代表性学术成果：
1. Ying Liu#, Wenjie Liu#, Ziqiang Yu, Yan Zhang, Yinghua Li, Dantao Xie, Gang Xie, Li Fan*, Shipeng He*. A novel BRD4 inhibitor suppresses osteoclastogenesis and ovariectomized osteoporosis by blocking RANKL-mediated MAPK and NF-κB pathways. Cell Death & Disease. 2021,12(7):654. doi: 10.1038/s41419-021-03939-7.
2. Wenjie Liu#, Gang Xie#, Guixin Yuan, Dantao Xie , Zhen Lian, Zihong Lin , Jiajie Ye, Wenyun Zhou , Weijun Zhou, Henghui Li, Xinjia Wang, Haotian Feng, Ying Liu* , Guanfeng Yao*. 6'-O-Galloylpaeoniflorin Attenuates Osteoclasto-genesis and Relieves Ovariectomy-Induced Osteoporosis by Inhibiting Reactive Oxygen Species and MAPKs/c-Fos/NFATc1 Signaling Pathway. Front Pharmacol. 2021,12:641277. doi: 10.3389/fphar.2021.641277.
3. Demeng Xia# , Sheng Wang# , Renqi Yao , Yuexue Han, Liyu Zheng , Pengyi He , Ying Liu*, Lu Yang*. Pyroptosis in sepsis: Comprehensive analysis of research hotspots and core genes in 2022. Front Mol Biosci.2022, 9:955991. doi: 10.3389/fmolb.2022.955991.
4. Qi Sun# , Yujie Wang# , Hong Ji #, Xiaoting Sun , Sisi Xie , Longtian Chen , Sen Li , Weifan Zeng , Ruibo Chen, Qi Tang, Ji Zuo , Likun Hou, Kayoko Hosaka , Yongtian Lu , Ying Liu* , Ying Ye *, Yunlong Yang*. Lenvatinib for effectively treating antiangiogenic drug-resistant nasopharyngeal carcinoma. Cell Death Dis. 2022,13(8):724. doi: 10.1038/s41419-022-05171-3.
5. Haitao Liu# , Panpan Zhang# , Xiaoxiao Ge#, Qiong Wu , Chuchu Han , Linyang Zhang , Yuxin Hua , Yuxuan Zhang , Jiping Liu, Yongheng Shi , Bin Wang , Xiaoping Wang, Wei Wang , Yi Jiang , Huawei Zhang , Chong Deng, Yundong Xie *, Ying Liu * , Shipeng He *. Optimization of clofibrate with O-desmethyl anetholtrithione lead to a novel hypolipidemia compound with hepatoprotective effect. Bioorg Med Chem Lett. 2022,72:128844. doi: 10.1016/j.bmcl.2022.128844.
6. Keyan Sun#, Huaxing Shen#, Shipeng He*, Ying Liu*. MASM inhibits cancer stem cell-like characteristics of EpCAM+ cells via AKT/GSK3β/β-catenin signaling. Am J Transl Res.2022,14(11):8380-8389.
7. Zhentao Zhang#, Shuo Wang#, Ye Lu, Demeng Xia*, Ying Liu*. TLR4 predicts patient prognosis and immunotherapy efficacy in clear cell renal cell carcinoma. Journal of Cancer. 2023.14(12):2181-2197. doi: 10.7150/jca.84502.
学术奖项：
“骨质疏松早期诊断代谢生物标志物筛选研究”项目获得上海大学转化医学科技成果评选三等奖（排名第三，2019年）。
科研项目：
1. 国家自然科学基金青年项目，新型BRD4/HDAC双靶抑制剂13a在乳腺癌骨转移中的作用及其机制研究，2022/1/1-2024/12/31，30万元，在研，主持；
2. 国防科技特区163计划12-18重点项目，TY效能数据库与测试体系构建关键技术研究，2019/9/1-2021/12/31，240万元，结题，主持;
3. 上海大学“青年英才启航计划”, MASM抑制肝癌干细胞及其机制研究，2022.09，10万元，结题，主持。
